Cost-effectiveness of the artificial liver support system MARS in patients with acute-on-chronic liver failure

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 2, 2010, Pages 213-220

  Hessel, Franz P ^a   Bramlage, Peter ^b   Wasem, Jurgen ^a   Mitzner, Steffen R ^c  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b Institute for Cardiovascular Pharmacology and Epidemiology   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Albumin dialysis; Cohort trial; Cost effectiveness; Quality adjusted life years; Survival

Indexed keywords

ACUTE EXACERBATION OF CHRONIC LIVER FAILURE; ADULT; ALBUMIN DIALYSIS; ARTICLE; ARTIFICIAL LIVER; CHRONIC DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; LIVER FAILURE; LIVER SUPPORT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; ALBUMINS; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; FEMALE; GERMANY; HOSPITAL COSTS; HOSPITAL MORTALITY; HUMANS; LEAST-SQUARES ANALYSIS; LIVER FAILURE, ACUTE; LIVER, ARTIFICIAL; MALE; MIDDLE AGED; MODELS, ECONOMIC; MONTE CARLO METHOD; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; SORPTION DETOXIFICATION; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 75749136159     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283314e48     Document Type: Article

References (29)

1. Sola R, Alvarez MA, Balleste B, Montoliu S, Rivera M, Miquel M, et al. Probability of liver cancer and survival in HCV-related or alcoholic- decompensated cirrhosis. A study of 377 patients. Liver Int 2006; 26:62-72.
2. The European Liver Patients Association. 2005 [cited 2008 20. 11. 2008]. Available at http://www. elpa-info. org
3. WHO. Hepatitis C. 2008 [cited 2008 27. 11. 2008]. Available at http:// www. who. int/immunization/topics/hepatitis-c/eng/index. html
4. Statistical Yearbook Germany. 2008 [cited 2008 07. 11. 2008]. Available at http://www. destatis. de/jetspeed/portal/cms/Sites/destatis/SharedContent/ Oeffentlich/AI/IC/Publikationen/Jahrbuch/Gesundheit, property =file. pdf.
5. Webb K, Neuberger J. Transplantation for alcoholic liver disease. BMJ 2004; 329:63-64.
6. Mitzner SR. Albumin dialysis: an update. Curr Opin Nephrol Hypertens 2007; 16:589-595.
7. Hassanein TI, Tofteng F, Brown RS Jr, McGuire B, Lynch P, Mehta R, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007; 46:1853-1862.
8. Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002; 36:949-958.
9. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6:277-286.
10. Sen S, Davies NA, Mookerjee RP, Cheshire LM, Hodges SJ, Williams R, et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl 2004; 10:1109-1119.
11. Mullhaupt B, Kullak-Ublick GA, Ambuhl P, Maggiorini M, Stocker R, Kadry Z, et al. First clinical experience with Molecular Adsorbent Recirculating System (MARS) in six patients with severe acute on chronic liver failure. Liver 2002; 22 (Suppl 2):59-62.
12. Wolff B, Machill K, Schumacher D, Schulzki I. MARS dialysis in decompensated alcoholic liver disease: a single-center experience. Liver Transpl 2007; 13:1189-1192.
13. Kurtovic J, Boyle M, Bihari D, Riordan SM. An Australian experience with the molecular adsorbents recirculating system (Mars). Ther Apher Dial 2006; 10:2-6.
14. Koivusalo AM, Vakkuri A, Hockerstedt K, Isoniemi H. Experience of Mars therapy with and without transplantation in 101 patients with liver insufficiency. Transplant Proc 2005; 37:3315-3317.
15. Steiner C, Mitzner S. Experiences with MARS liver support therapy in liver failure: analysis of 176 patients of the International MARS Registry. Liver 2002; 22 (Suppl 2):20-25.
16. Hessel FP, Mitzner SR, Rief J, Guellstorff B, Steiner S, Wasem J. Economic evaluation and 1-year survival analysis of MARS in patients with alcoholic liver disease. Liver Int 2003; 23 (Suppl 3):66-72.
17. Hessel FP, Mitzner SR, Rief J, Gress S, Guellstorff B, Wasem J. Economic evaluation of MARS - preliminary results on survival and quality of life. Liver 2002; 22 (Suppl 2):26-29.
18. Hessel FP. Economic evaluation of the artificial liver support system MARS in patients with acute-on-chronic liver failure. Cost Eff Resour Alloc 2006; 4:16.
19. Schulenburg von der JM, Claes C, Greiner W, Uber A. The German version of the Euroquol questionnaire. Zeitschrift für Gesundheitswissenschaften 1998; 11:3-20.
20. Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998; 51:1171-1178.
21. Krauth C, Hessel F, Hansmeier T, Wasem J, Seitz R, Schweikert B. [Empirical standard costs for health economic evaluation in Germany - a proposal by the working group methods in health economic evaluation]. Gesundheitswesen 2005; 67:736-746.
22. Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies. 3rd ed. Ottawa: CADTH; 2006.
23. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York, Oxford: Oxford University Press; 1996.
24. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997; 6:327-340.
25. Liu JP, Gluud LL, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for liver failure. Cochrane Database Syst Rev 2004; CD003628.
26. Khuroo MS, Farahat KL. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl 2004; 10:1099-1106.
27. Doria C, Mandala L, Smith J, Vitale CH, Lauro A, Gruttadauria S, et al. Effect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus. Liver Transpl 2003; 9:437-443.
28. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004; 329:224-227.
29. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20:332-342.